Semiannual Securities Report — FY2026 H1
What Fuso Pharmaceutical Industries,Ltd. reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-11View the original on EDINET
How much it says
52Typical
What moved here
8named for the first time
Its own wording
24terms
Which filing this is
38/ 38newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim accounting period, net sales increased, as did profit (operating profit, ordinary profit, and interim net income). At the same time, the filing mentions research and development expenses and capital expenditures (investing activities in the statement of cash flows), as well as the execution of a design and construction contract for the Okayama No. 2 Plant and a license agreement for DMX-200.
Komori's summary of this document, not the document's own words.52Typical
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 34 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
31
Thin
78
Very detailed
50
Typical
68
Detailed
0
Almost nothing
100
Very detailed
7
Almost nothing
55
Typical
50
Typical
R&D spend67億円Money spent making new things.
Cash left over65億円Cash from the business, less what went into equipment.
Spent on equipment140億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.